Artal Group’s Moderna MRNA Stock Holding History

Artal Group’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-500,000	Closed	-$9.78M	–	108
2019 Q4	$9.78M	Hold	500,000	–	–	0.38%	48
2019 Q3	$7.96M	Hold	500,000	–	–	0.32%	57
2019 Q2	$7.32M	Buy	+500,000	New	+$10.7M	0.3%	67

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

Artal Group's MRNA Position: Q1 2021 in Review

Artal Group sold out of Moderna (MRNA) in Q1 2021, closing a stake of 50,000 shares — an estimated $5.22M sold.

Artal Group first reported a position in MRNA in Q4 2018 and held it in 9 quarters. The position peaked at $102M in Q1 2019. 776 funds tracked by Wall St. Rank hold MRNA as of Q1 2021.

Artal Group reported no remaining Moderna position as of Q1 2021 after selling out during the quarter.
Artal Group sold 50,000 Moderna shares in Q1 2021, an estimated $5.22M.
Artal Group first reported a position in Moderna in Q4 2018 and held it in 9 quarters.
Artal Group's Moderna position peaked at $102M in Q1 2019.
776 funds tracked by Wall St. Rank held Moderna as of Q1 2021.

Based on Artal Group's 13F filing for Q1 2021, filed 14 May 2021.